Bromocriptine

Bromocriptine
Clinical data
Trade namesOriginally Parlodel, subsequently many[1]
Other names2-Bromoergocriptine; CB-154
AHFS/Drugs.comMonograph, International Drug Names
MedlinePlusa682079
Pregnancy
category
  • AU: A
Routes of
administration		By mouth, vaginal, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability28% of oral dose absorbed
MetabolismExtensively liver-mediated
Elimination half-life12–14 hours
Excretion85% bile (feces), 2.5–5.5% urine
Identifiers
  • (5′α)-2-Bromo-12′-hydroxy-5′-(2-methylpropyl)-3′,6′,18-trioxo-2′-(propan-2-yl)ergotaman
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.042.829 Edit this at Wikidata
Chemical and physical data
FormulaC32H40BrN5O5
Molar mass654.606 g·mol−1
3D model (JSmol)
  • BrC1=C(C[C@H]2N(C)C3)C4=C(C=CC=C4C2=C[C@H]3C(N[C@]5(C(C)C)O[C@@]6(N([C@@H](CC(C)C)C(N7CCC[C@H]76)=O)C5=O)O)=O)N1
  • InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1 checkY
  • Key:OZVBMTJYIDMWIL-AYFBDAFISA-N checkY
  (verify)

Bromocriptine, originally marketed as Parlodel and subsequently under many brand names,[1] is an ergoline derivative and dopamine agonist that is used in the treatment of pituitary tumors, Parkinson's disease, hyperprolactinaemia, neuroleptic malignant syndrome, and, as an adjunct, type 2 diabetes.

It was patented in 1968 and approved for medical use in 1975.[2]

  1. ^ a b Cite error: The named reference brands was invoked but never defined (see the help page).
  2. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 533. ISBN 9783527607495.